I am serious. I bought and wanted to hold for what
Post# of 15624
(Total Views: 278)
Posted On: 06/08/2017 6:38:17 PM
I am serious. I bought and wanted to hold for what is STILL expected in Q3/Q4.
Multiple Myeloma! Revenue should have STARTED by then, but maybe nothing significant.
I want to see if the Cancer study can entice a BUYOUT even.
Same stuff you were hoping for back in February. The 8Ks and PRs tell me they're still ON TRACK for that kind of stuff!
And, forgive me for sounding cranky... I just hate that I have busy/stressful days with my day job and then see bullshit from morons like I-Glow and then see other messages about how this stock is going to slowly bleed...
I don't believe it. We're sitting around $92 MILLION Market Cap without ANY REVENUE, with NO PRODUCT on the market. That is still impressive. We've held this PPS range for a while too. THAT is impressive.
It leads me to NOT DOUBT that we can and will run back into multiple-dollars when some big updates hit.
I still predict another partnership, some patent updates, more efficacy testing, etc. Second half of 2017 will be beautiful, IMO.
Multiple Myeloma! Revenue should have STARTED by then, but maybe nothing significant.
I want to see if the Cancer study can entice a BUYOUT even.
Same stuff you were hoping for back in February. The 8Ks and PRs tell me they're still ON TRACK for that kind of stuff!
And, forgive me for sounding cranky... I just hate that I have busy/stressful days with my day job and then see bullshit from morons like I-Glow and then see other messages about how this stock is going to slowly bleed...
I don't believe it. We're sitting around $92 MILLION Market Cap without ANY REVENUE, with NO PRODUCT on the market. That is still impressive. We've held this PPS range for a while too. THAT is impressive.
It leads me to NOT DOUBT that we can and will run back into multiple-dollars when some big updates hit.
I still predict another partnership, some patent updates, more efficacy testing, etc. Second half of 2017 will be beautiful, IMO.
(2)
(0)